These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35293439)

  • 21. Biological factors that impinge on Chagas disease drug development.
    Francisco AF; Jayawardhana S; Lewis MD; Taylor MC; Kelly JM
    Parasitology; 2017 Dec; 144(14):1871-1880. PubMed ID: 28831944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
    Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amaryllidaceae plants: a potential natural resource for the treatment of Chagas disease.
    Martínez-Peinado N; Cortes-Serra N; Tallini LR; Pinazo MJ; Gascon J; Bastida J; Alonso-Padilla J
    Parasit Vectors; 2021 Jun; 14(1):337. PubMed ID: 34174959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.
    Brand S; Ko EJ; Viayna E; Thompson S; Spinks D; Thomas M; Sandberg L; Francisco AF; Jayawardhana S; Smith VC; Jansen C; De Rycker M; Thomas J; MacLean L; Osuna-Cabello M; Riley J; Scullion P; Stojanovski L; Simeons FRC; Epemolu O; Shishikura Y; Crouch SD; Bakshi TS; Nixon CJ; Reid IH; Hill AP; Underwood TZ; Hindley SJ; Robinson SA; Kelly JM; Fiandor JM; Wyatt PG; Marco M; Miles TJ; Read KD; Gilbert IH
    J Med Chem; 2017 Sep; 60(17):7284-7299. PubMed ID: 28844141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
    Beltran-Hortelano I; Perez-Silanes S; Galiano S
    Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
    Duschak VG
    Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mammea type coumarins isolated from Calophyllum brasiliense induced apoptotic cell death of Trypanosoma cruzi through mitochondrial dysfunction, ROS production and cell cycle alterations.
    Rodríguez-Hernández KD; Martínez I; Reyes-Chilpa R; Espinoza B
    Bioorg Chem; 2020 Jul; 100():103894. PubMed ID: 32388434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trypanocidal treatment of Chagas disease.
    Pérez-Molina JA; Crespillo-Andújar C; Bosch-Nicolau P; Molina I
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Nov; 39(9):458-470. PubMed ID: 34736749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi.
    Sangenito LS; Menna-Barreto RFS; d'Avila-Levy CM; Branquinha MH; Santos ALS
    Curr Med Chem; 2019; 26(36):6590-6613. PubMed ID: 31187704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug discovery for chagas disease: A viewpoint.
    Kratz JM
    Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trypanocidal activity and selectivity in vitro of aromatic amidine compounds upon bloodstream and intracellular forms of Trypanosoma cruzi.
    De Souza EM; da Silva PB; Nefertiti AS; Ismail MA; Arafa RK; Tao B; Nixon-Smith CK; Boykin DW; Soeiro MN
    Exp Parasitol; 2011 Feb; 127(2):429-35. PubMed ID: 20971106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo trypanocidal activity of a benzofuroxan derivative against Trypanosoma cruzi.
    Dos Santos Petry L; Pillar Mayer JC; de Giacommeti M; Teixeira de Oliveira D; Razia Garzon L; Martiele Engelmann A; Magalhães de Matos AFI; Dellaméa Baldissera M; Dornelles L; Melazzo de Andrade C; Gonzalez Monteiro S
    Exp Parasitol; 2021; 226-227():108125. PubMed ID: 34129877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The translational challenge in Chagas disease drug development.
    Kratz JM; Gonçalves KR; Romera LM; Moraes CB; Bittencourt-Cunha P; Schenkman S; Chatelain E; Sosa-Estani S
    Mem Inst Oswaldo Cruz; 2022; 117():e200501. PubMed ID: 35613156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
    Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
    Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recognition for Chagas disease.
    Burki T
    Lancet Infect Dis; 2019 Jul; 19(7):699. PubMed ID: 31250822
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of phthalazinone phosphodiesterase inhibitors with improved activity and selectivity against Trypanosoma cruzi.
    De Araújo JS; da Silva PB; Batista MM; Peres RB; Cardoso-Santos C; Kalejaiye TD; Munday JC; De Heuvel E; Sterk GJ; Augustyns K; Salado IG; Matheeussen A; De Esch I; De Koning HP; Leurs R; Maes L; Soeiro MNC
    J Antimicrob Chemother; 2020 Apr; 75(4):958-967. PubMed ID: 31860098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of Chagas disease chemotherapy.
    Guedes PM; Silva GK; Gutierrez FR; Silva JS
    Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates.
    Padilla AM; Wang W; Akama T; Carter DS; Easom E; Freund Y; Halladay JS; Liu Y; Hamer SA; Hodo CL; Wilkerson GK; Orr D; White B; George A; Shen H; Jin Y; Wang MZ; Tse S; Jacobs RT; Tarleton RL
    Nat Microbiol; 2022 Oct; 7(10):1536-1546. PubMed ID: 36065062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
    Sulleiro E; Muñoz-Calderon A; Schijman AG
    Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repositioning of leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salts for Chagas disease treatment: Trypanosoma cruzi cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition.
    Martín-Escolano R; Martín-Escolano J; Ballesteros-Garrido R; Cirauqui N; Abarca B; Rosales MJ; Sánchez-Moreno M; Ballesteros R; Marín C
    Parasitol Res; 2020 Sep; 119(9):2943-2954. PubMed ID: 32607710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.